TTPH Tetraphase Pharmaceuticals Inc.

1.19
+0.02  (+2%)
Previous Close 1.17
Open 1.17
Price To Book 0.66
Market Cap 63814603
Shares 53,625,717
Volume 135,031
Short Ratio
Av. Daily Volume 704,456

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial to be completed 2Q 2019.
TP-271
Community-acquired bacterial pneumonia (CABP)

Latest News

  1. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Tetraphase Pharmaceuticals, Inc. (TTPH) and Encourages TTPH Investors to Contact the Firm
  2. Robbins Arroyo LLP: Shareholders Allege That Tetraphase Pharmaceuticals, Inc. (TTPH) Misled Shareholders
  3. New Research: Key Drivers of Growth for Tetraphase Pharmaceuticals, Olympic Steel, Belden, KAR Auction Services, BWX Technologies, and Sparton — Factors of Influence, Major Initiatives and Sustained Production
  4. Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
  5. Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments
  6. Edited Transcript of TTPH earnings conference call or presentation 8-Nov-18 9:30pm GMT
  7. Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates
  8. Tetraphase: 3Q Earnings Snapshot
  9. War against the superbugs: Mass. biotechs step up to fight antibiotic resistance
  10. Is Tetraphase Pharmaceuticals Inc’s (NASDAQ:TTPH) Balance Sheet Strong Enough To Weather A Storm?
  11. Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock
  12. DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572607
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19552459
  3. CT ORDER - Confidential treatment order 181242367
  4. CT ORDER - Confidential treatment order 181171880
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171028
  6. 8-K - Current report 181169783
  7. 8-K - Current report 181160010
  8. 8-K - Current report 181079228
  9. 8-K - Current report 181040307
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988201